CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Lopinavir 200Mg/Ritonavir 50Mg FT ReferenceWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1361 Lopinavir 200Mg/Ritonavir 50Mg FT Test Wiki 1.00
drug1359 Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride Wiki 1.00
drug2704 Xiyanping injection Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Randomized, Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over Trial to Assess the BE of Orvical 200 mg/50 mg FT in Comparison With Kaletra 200 mg/50 mg FT in Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination and a single dose of Test product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions.

NCT04386876 Bioequivalence Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Test Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Reference

Primary Outcomes

Description: AUC0-tlast of lopinavir and ritonavir

Measure: Primary PK End Points

Time: 12 weeks

Description: Cmax of lopinavir and ritonavir

Measure: Primary PK End Points

Time: 13 weeks

No related HPO nodes (Using clinical trials)